李慧敏,陈光.论数据驱动创新与个人信息保护的冲突与平衡——基于对日本医疗数据规制经验的考察[J].中国科学院院刊,2020,35(9):1143-1151.

论数据驱动创新与个人信息保护的冲突与平衡——基于对日本医疗数据规制经验的考察

On Conflict and Balance Between Data-driven Innovation and Personal Information Protection—A Study of Japan's Medical Data Regulation Experience
作者
李慧敏
中国科学院科技战略咨询研究院 北京 100190
LI Huimin
Institutes of Science and Development, Chinese Academy of Sciences, Beijing 100190, China
陈光
中国科学院 学部工作局 北京 100190
CHEN Guang
Bureau of Academic Divisions, Chinese Academy of Sciences, Beijing 100190, China
中文关键词
         医疗数据;个人信息保护法;次世代医疗基础法;匿名加工制度;日本
英文关键词
        medical data;personal information protection law;the Next Generation Medical Infrastructure Act;anonymous processing system;Japan
中文摘要
        如何把握数据驱动创新与个人信息保护之间的平衡,深刻影响一国数字经济发展的未来,尤其在医疗数据等敏感个人数据领域。日本在医疗数据规制领域建立“基本法+专门法”双层法律体系,并在操作层面创设“匿名加工+认定”制度,以平衡医疗大数据开发与个人信息保护之间的关系,形成独树一格的日本式规制模式。针对我国在个人信息保护和数据开发利用2个方面立法滞后、制度不健全的现状,建议:(1)加快推进数据保护体系构建,弥补“保护缺位”;(2)系统思考数据保护与运用的平衡关系,探索实效性发展举措,弥补“发展缺位”;(3)借鉴日本经验做法,为推进医疗数据开发利用,完善相关配套制度。
英文摘要
        How to balance the relationship between the development of data and personal information protection, is an important problem affecting the development of digital economy of the country, especially in the field of sensitive personal data such as medical data. In the medical field, Japan formed its own regulation system according to its domestic situation. Based on the experiences of Japan, this study proposed some suggestions which would improve our concerned systems. (1) China is not yet having specific personal information protection legislation, let alone a set of effective personal information protection legal system. So, a special law should be formulated to protect the right of personal information, and be perfected as soon as possible from the aspect of protection of right of privacy of the citizen in China. (2) China shall attach great importance to the development and application of personal data and medical data, and design the relevant regulations. (3) Anonymity and opt-out requirements are used in personal information protection. Japan has accumulated much mature experience in medical data regulation, which is worthy of being drawn upon by regulators in China.
DOI10.16418/j.issn.1000-3045.20200522002
作者简介
李慧敏 中国科学院科技战略咨询研究院副研究员。日本早稻田大学经济法学博士。主要研究方向为反垄断法、科技产业政策。主持国家社科基金项目、日本亚洲研究项目等国内外项目10余项,出版日文专著1部。
E-mail:lihuimin@casisd.cn
LI Huimin Associate Professor at the Institutes of Science and Development,Chinese Academy of Sciences (CASISD).Received the doctor's degree in law from Waseda University of Japan,in 2015.Her research focuses on antitrust law and industrial policies.As project leader or co-project leader,she has completed more than ten projects of national social sciences founding project,Japan-Related Research Projects,etc,and also published a monograph in Japanese.
E-mail:lihuimin@casisd.cn
陈光 中国科学院学部工作局咨询与科普教育处副处长、副研究员。中国科学院-马普学会联合培养博士。主要研究方向为科学经济学、科技政策。主持省部级项目10余项。
E-mail:chenguang@cashq.ac.cn
CHEN Guang Deputy Director of Division of Consultation&Science Publicity,Bureau of Academic Divisions of Chinese Academy of Sciences (CAS).Received the Doctor's degree in management from University of Chinese Academy of Sciences in 2008.He studies on the economics of science,science and technology policy.
E-mail:chenguang@cashq.ac.cn
微信关注公众号